Bio developments

© Getty Images

FDA lifts partial clinical hold on phase 3 low blood sugar treatment

By Larissa Worneck-Silvestrin

Rare disease biotech Rezolute recently announced that the FDA has lifted the partial clinical hold on RZ358 (ersodetug), a novel therapy in development for the treatment of low blood sugar (hypoglycemia) resulting from congenital hyperinsulinism.